This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Clinical Trial With Fusaric Acid

Robert L. Sack, MD; Frederick K. Goodwin, MD

Arch Gen Psychiatry. 1974;31(5):649-654.

Abstract
Behavioral effects of fusaric acid, a specific inhibitor of dopaminebeta-hydroxylase (DBH), were evaluated under double-blind conditions in manic patients. Inhibition of DBH selectively decreases central norepinephrine (NE) without a decrease in dopamine and thus provides a test of the NE hypothesis of mania. Fusaric acid administration was associated with a significant decrease in cerebrospinal fluid 3-methoxy-4-hydroxy-phenylglycol (the major metabolite of NE) and an increase in homovanillic acid (the major metabolite of dopamine), changes consistent with central DBH inhibition.

Behavioral effects of fusaric acid appeared to depend on the preexisting clinical state. Patients with more severe mania, including evidence of preexisting psychotic features, became consistently worse (more psychotic), while patients with mild hypomanic symptoms showed no change or slight improvement. Conventional antimanic therapies, initiated after the fusaric acid protocol, were associated with improvement in the expected time period in all patients.

Author Affiliations
From the Section on Psychiatry, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Md (Dr. Goodwin). Dr. Sack is now with the Department of Psychiatry, Stanford University, School of-Medicine, Palo Alto, Calif.

Footnotes
Accepted for publication Aug 8, 1974.

Reprint requests to the Section on Psychiatry, LCS/NIMH, 9000 Rockville Pike, Bldg 10, Rm 4S239, Bethesda, MD 20014 (Dr. Goodwin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

PET Study of [18F]6-Fluoro-L-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium
Yatham et al.
Am. J. Psychiatry 2002;159:768-774.
ABSTRACT | FULL TEXT  

In Vivo D2 Dopamine Receptor Density in Psychotic and Nonpsychotic Patients With Bipolar Disorder
Pearlson et al.
Arch Gen Psychiatry 1995;52:471-477.
ABSTRACT  

Schizophrenia: dopamine beta-hydroxylase activity and treatment response
Sternberg et al.
Science 1982;216:1423-1425.
ABSTRACT  

Mode of Action of Lithium: Some Biological Considerations
Bunney et al.
Arch Gen Psychiatry 1979;36:898-901.
ABSTRACT